3-aminobenzamide has been researched along with Idiopathic Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, XL | 1 |
| Wang, P | 1 |
| Liu, YH | 1 |
| Xue, YX | 1 |
| Chiba-Falek, O | 1 |
| Kowalak, JA | 1 |
| Smulson, ME | 1 |
| Nussbaum, RL | 1 |
2 other studies available for 3-aminobenzamide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson's disease.
Topics: Animals; Benzamides; Blood-Brain Barrier; Claudin-5; Dopaminergic Neurons; Interleukin-1beta; Lipopo | 2014 |
Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene.
Topics: Alleles; alpha-Synuclein; Base Sequence; Benzamides; Binding Sites; Cell Line; DNA; Enzyme Inhibitor | 2005 |